Inspire Medical Systems, Inc. (INSP)

Environment story

Inspire Medical Systems operates as a medical device manufacturer with minimal direct operational carbon footprint disclosure. The company manufactures implantable neurostimulation devices for sleep apnea treatment and outsources manufacturing to third-party suppliers located primarily in the U.S. Environmental emissions (Scope 1, Scope 2, and Scope 3) are not disclosed in the 10-K filing. No net-zero target year is stated. No sustainability report, GHG inventory, or climate commitments are evident in the provided documents. The company does not report renewable energy percentages or decarbonization initiatives. No material environmental controversies (toxic waste, water consumption, habitat damage) are identified. Manufacturing facility inspections by FDA occur but environmental compliance details are not disclosed. The company faces potential environmental impact from supply chain (third-party suppliers, single-source dependencies) but supply chain environmental audits are not mentioned. Score reflects lack of disclosed environmental metrics and net-zero targets (−15 for undisclosed Scope 3; −15 for no stated net-zero target; no offset or greenwashing detected).

Social story

Inspire Medical Systems reports no CEO-to-median-worker pay ratio disclosure in the 10-K; executive compensation details are not provided in the source documents. Turnover rate is not disclosed. Union standing is not mentioned; no documented labor disputes, NLRB complaints, strikes, or union-suppression activities are identified in the provided materials. Diversity metrics for executive and board leadership are not explicitly stated in the 10-K excerpts provided. The company emphasizes hiring and retaining senior management and highly qualified personnel as a strategic priority, but no formal diversity targets or metrics are disclosed. Supply-chain ethics are not detailed; the company relies on third-party suppliers and contract manufacturers with a rigorous supplier assessment process per FDA and ISO standards, but no human-rights audits, conflict minerals policy, or modern slavery statements are referenced. No controversies related to labor practices, workplace safety litigation, or supply-chain human-rights violations are identified. Score reflects lack of disclosed diversity metrics (−15), absence of CEO-to-worker ratio data, and no supply-chain human-rights audit disclosures.

Governance story

Inspire Medical Systems does not disclose board independence percentage or board composition details in the provided 10-K excerpts. Share structure is not explicitly described; no dual-class voting rights are mentioned, suggesting single-class structure. Lobbying expenditures are not disclosed in the documents provided. No active antitrust proceedings, consumer-safety regulatory actions, or financial-fraud proceedings are identified. The company faces patent litigation with Nyxoah regarding intellectual property portfolio (multiple adversarial proceedings noted), but this is a commercial IP dispute rather than regulatory enforcement. The company mentions risks related to evolving focus on ESG initiatives and sustainability reporting. No evidence of climate-deregulation lobbying, environmental-protection rollback advocacy, or consumer-protection statute weakening is present. No shareholder activism or proposals are described in the provided materials. Score reflects lack of disclosed board independence metrics (−15) and absence of lobbying disclosure data; no material governance controversies identified.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Inspire Medical Systems, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Inspire Medical Systems, Inc. in the app for interactive charts and portfolio building.

More in Healthcare